Regeneron Pharmaceuticals, Inc. (REGN)
NASDAQ: REGN · Real-Time Price · USD
772.11
+3.53 (0.46%)
Aug 6, 2026, 4:00 PM EDT - Market closed
Regeneron Pharmaceuticals Stock Forecast
Stock Price Forecast
According to 27 analysts polled by S&P Global, Regeneron Pharmaceuticals stock has a consensus rating of "Buy" and an average price target of $833.54. The average 1-year stock price forecast is 7.96% higher than the current stock price, while the lowest is $641 (-16.98%) and the highest is $1,030 (+33.40%).
Price Target: $833.54 (+7.96%)
Analyst Consensus: Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Regeneron Pharmaceuticals stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Mar '26 | Apr '26 | May '26 | Jun '26 | Jul '26 | Aug '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 18 | 18 | 16 | 16 | 14 | 14 |
| Buy | 4 | 4 | 5 | 5 | 4 | 4 |
| Hold | 7 | 7 | 8 | 8 | 9 | 9 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 29 | 29 | 29 | 29 | 27 | 27 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| J.P. Morgan | J.P. Morgan | Buy Maintains $850 → $900 | Buy | Maintains | $850 → $900 | +16.56% | Aug 5, 2026 |
| Barclays | Barclays | Buy Maintains $917 | Buy | Maintains | $917 | +18.77% | Aug 5, 2026 |
| Guggenheim | Guggenheim | Buy Maintains $1,000 → $1,030 | Buy | Maintains | $1,000 → $1,030 | +33.40% | Aug 3, 2026 |
| Citi | Citi | Hold Maintains $700 → $740 | Hold | Maintains | $700 → $740 | -4.16% | Aug 3, 2026 |
| BMO Capital | BMO Capital | Buy Maintains $730 → $800 | Buy | Maintains | $730 → $800 | +3.61% | Jul 31, 2026 |
Financial Forecast
Revenue This Year
16.89B
from 14.34B
Increased by 17.75%
Revenue Next Year
18.34B
from 16.89B
Increased by 8.59%
EPS This Year
53.00
from 44.31
Increased by 19.62%
EPS Next Year
60.11
from 53.00
Increased by 13.40%
EPS and Forward PE are based on non-GAAP adjusted numbers.